Skip to main content

Table 2 Population characteristics: training, validation and test subgroups

From: Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance

 

All

n = 206

Training subgroup

n = 134 (65%)

Validation subgroup

n = 30 (15%)

Test

subgroup

n = 42 (20%)

p-value

Age (years)

76 (69–81)

77 (69–81)

71 (65–79)

73 (63–79)

0.097

Male sex (n, %)

137 (67)

88 (66)

20 (67)

29 (69)

0.623

BSA (m2)

1.84 (1.74–1.96)

1.83 (1.73–1.95)

1.88 (1.75–2.02)

1.85 (1.76–1.95)

0.206

Amyloidosis (n, %)

107 (52)

71 (53)

15 (50)

21 (50)

0.645

AL/ATTR/no amyloidosis (n, %)

50/57/99 (24/28/48)

33/38/63 (25/28/47)

6/9/15 (20/30/50)

11/10/21 (26/24/50)

0.610

CMR findings

LVEDVI (mL/m2)

79 (67–96)

79 (64–95)

71 (66–92)

84 (70–106)

0.105

LVESVI (mL/m2)

33 (23–50)

31 (23–50)

27 (20–42)

40 (26–56)

0.112

LVSVI (mL/m2)

44 (37–51)

42 (37–49)

44 (39–52)

47 (38–54)

0.131

LVEF (%)

55 (46–67)

56 (47–67)

62 (51–70)

53 (45–64)

0.277

CO (L/min)

5.3 (4.3–6.6)

5.1 (4.3–6.3)

5.5 (5.1–7.3)

5.5 (4.4–7.0)

0.565

LVMI (g/m2)

84 (71–111)

88 (71–114)

82 (70–113)

82 (73–107)

0.730

LA area index (cm2/m2)

16 (13–18)

15 (13–18)

17 (13–18)

16 (14–18)

0.714

RA area index (cm2/m2)

13 (11–15)

13 (11–15)

13 (10–17)

13 (12–15)

0.742

RVEDVI (mL/m2)

70 (57–81)

66 (55–80)

71 (55–89)

73 (62–81)

0.212

RVESVI (mL/m2)

28 (20–37)

28 (20–37)

27 (19–34)

30 (22–37)

0.180

RVSVI (mL/m2)

39 (33–47)

38 (33–44)

40 (34–52)

42 (34–51)

0.624

RVEF (%)

59 (47–65)

59 (49–64)

60 (49–67)

60 (47–65)

0.468

Early darkening (n, %)

40 (19)

26 (19)

8 (27)

6 (14)

0.241

LGE presence (n, %)

174 (84)

115 (86)

25 (83)

34 (81)

0.954

LGE subendocardial-to-transmural pattern (n, %)

89 (43)

61 (46)

11 (37)

18 (43)

0.434

Pericardial effusion (n, %)

48 (23)

32 (22)

4 (13)

12 (29)

0.465

Pleural effusion (n, %)

58 (28)

39 (27)

7 (23)

12 (29)

0.606

  1. AL amyloid light-chain, ATTR amyloid transthyretin, BSA body surface area, CMR cardiovascular magnetic resonance, CO cardiac output, LA left atrium, LGE late gadolinium enhancement, LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, LVSVI left ventricular stroke volume index, RA right atrium, RVEDVI right ventricular end-diastolic volume index, RVESVI right ventricular end-systolic volume index, RVEF right ventricular ejection fraction, RVSVI right ventricular stroke volume index